Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9342 USD | +5.55% | +4.11% | +65.35% |
Financials (USD)
Sales 2024 * | 72.54M | Sales 2025 * | 68.35M | Capitalization | 172M |
---|---|---|---|---|---|
Net income 2024 * | -168M | Net income 2025 * | -167M | EV / Sales 2024 * | 0.78 x |
Net cash position 2024 * | 115M | Net cash position 2025 * | 281M | EV / Sales 2025 * | -1.61 x |
P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-1.4
x | Employees | 137 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
Latest transcript on Nektar Therapeutics
1 day | +5.55% | ||
1 week | +4.11% | ||
Current month | +31.58% | ||
1 month | +29.75% | ||
3 months | +69.24% | ||
6 months | +53.15% | ||
Current year | +65.35% |
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 17 M€ | -0.46% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.9342 | +5.55% | 1,316,239 |
24-03-27 | 0.8851 | -1.66% | 1,241,878 |
24-03-26 | 0.9 | +1.34% | 1,467,857 |
24-03-25 | 0.8881 | -2.78% | 1,708,466 |
24-03-22 | 0.9135 | +1.81% | 778,497 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.35% | 172M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |